Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...
Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after ...
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...
The company has been doing incredibly well, and revenue as well as profits have skyrocketed in recent quarters. Shares of ...
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...
Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...